{"id":"3b204106-8abd-4b8d-8536-8e8788e9b7aa","url":"content/3b204106-8abd-4b8d-8536-8e8788e9b7aa","title":"Tumour that is larger than 0.1 cm but smaller than 1 cm (T1a or T1b)","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic recommendation commentable-section\" data-annot-id=\"topic.dita_58473e7d-6dbf-4969-8eab-93638697356f\" id=\"topic.dita_58473e7d-6dbf-4969-8eab-93638697356f\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  \n  <div class=\"body recommendation-text\">\n    <p class=\"p\">Consider adjuvant trastuzumab if the person has early HER2-positive invasive breast cancer and a tumour that is larger than 0.1 cm but smaller than 1 cm (T1a or T1b). </p>\n  </div>\n \n</article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835128","url_s":"content/3b204106-8abd-4b8d-8536-8e8788e9b7aa","title_s":"Tumour that is larger than 0.1 cm but smaller than 1 cm (T1a or T1b)","nextTopic_s":"1f11b0db-e73e-4f23-ba32-54f1dba5ca11","prevTopic_s":"7006b96b-a7ee-48b1-afe9-7713e22ed10f"},"nice":{"nice_infotype_s":"recommendation","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":"","nice_condition-disease_s":"BreastCancer","nice_recommendation-strength_s":"weak","nice_change-in-practice_s":"no"}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"3b204106-8abd-4b8d-8536-8e8788e9b7aa","contentjoinuuid":"f0a2d9f6-e65c-42f5-adf6-feb17d90e043","contentjoinuuids":["f0a2d9f6-e65c-42f5-adf6-feb17d90e043","b6411394-b182-48a0-932b-feab3de553ac"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}